Search

Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 16 Issue: 1 Year: 2016 Page: 29-37
Author(s): Kevin M. Sokolowski,Steven Koprowski,Selvi Kunnimalaiyaan,Mariappan Balamurugan,T. Clark Gamblin,Muthusamy Kunnimalaiyaan

Inhibition of Akt/mTOR Signaling by the Dietary Flavonoid Fisetin

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 13 Issue: 7 Year: 2013 Page: 995-1001
Author(s): Deeba N. Syed, Vaqar M. Adhami, Mohammad Imran Khan, Hasan Mukhtar

Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin

Journal: Current Cancer Drug Targets
Volume: 16 Issue: 4 Year: 2016 Page: 288-304
Author(s): Zhipeng Zou,Juan Chen,Jun Yang,Xiaochun Bai

Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy

Journal: Current Medicinal Chemistry
Volume: 22 Issue: 24 Year: 2015 Page: 2858-2870
Author(s): C. Hu,L. Sun,L. Xiao,Y. Han,X. Fu,X. Xiong,X. Xu,Y. Liu,S. Yang,F. Liu,Y.S. Kanwar

EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance

Journal: Current Molecular Pharmacology
Volume: 3 Issue: 1 Year: 2010 Page: 37-52
Author(s): Hui-Wen Lo

Journal: Current Clinical Pharmacology
Volume: 5 Issue: 4 Year: 2010 Page: 281-287
Author(s): Wai M. Liu, Daniel W. Fowler, Angus G. Dalgleish

Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma

Journal: Current Cancer Drug Targets
Volume: 13 Issue: 2 Year: 2013 Page: 126-142
Author(s): Daniel C. Cho, James W. Mier

The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer

Journal: Current Pharmaceutical Biotechnology
Volume: 16 Issue: 9 Year: 2015 Page: 804-815
Author(s): Andrea Nicolini,Paola Ferrari,Lucie Kotlarova,Giuseppe Rossi,Pier M. Biava

Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy

Journal: Current Signal Transduction Therapy
Volume: 6 Issue: 1 Year: 2011 Page: 44-54
Author(s): Ota Fuchs

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors

Journal: Current Medicinal Chemistry
Volume: 18 Issue: 1 Year: 2011 Page: 2686-2714
Author(s): S. J. Shuttleworth, F. A. Silva, A. R.L. Cecil, C. D. Tomassi, T. J. Hill, F. I. Raynaud, P. A. Clarke, P. Workman